As the year draws to a close, we bring you the final edition of Editors’ Picks for 2020. This monthly roundup features one “must read” article, handpicked by the editors, from each journal issue published by the AACR. Studies highlighted in this post include a review article...
The U.S. FDA has approved a new targeted therapy for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies.
New therapies provide hope and options for people as they monitor and manage this incurable blood cancer.
Sophisticated blood tests offer a less invasive way to characterize cancers, guide treatment and catch recurrences sooner, but tissue biopsies remain the gold standard.
Using deep learning to detect tumor mutations.
Study suggests far-reaching benefits of mental health treatment.
Dental screening before treatment could stave off dental emergencies.
Hypofractionation may allow patients to finish radiation treatment sooner.
Whether lung cancer patients receive PET scans depends on race, according to a study.
Research on premalignancy is needed to fully tap the potential of cancer interception.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now